| Dr Yian Jin Jones, MD | |
|
4405 Hamilton Blvd, Sioux City, IA 51104-1140 | |
| (712) 239-3937 | |
| (712) 239-4946 |
| Full Name | Dr Yian Jin Jones |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 20 Years |
| Location | 4405 Hamilton Blvd, Sioux City, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689883464 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 7496 (South Dakota) | Secondary |
| 207W00000X | Ophthalmology | 38529 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Regional Medical Center | Sioux city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jones Eye Center Pc | 4385729094 | 3 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).
The Nordic Public Health Prize 2011 will be awarded to Professor of Psychiatry Jouko Lönnqvist for his internationally acclaimed research on the causes, spread and prevention of mental illness at population- and individual level.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Use of low-dose aspirin prior to a newer type of fecal occult blood test is associated with a higher sensitivity for detecting advanced colorectal tumors, compared to no aspirin use, according to a study in the December 8 issue of JAMA.
› Verified 4 days ago
| Entity Name | Jones Eye Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164605192 PECOS PAC ID: 4385729094 Enrollment ID: O20080305000324 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).
The Nordic Public Health Prize 2011 will be awarded to Professor of Psychiatry Jouko Lönnqvist for his internationally acclaimed research on the causes, spread and prevention of mental illness at population- and individual level.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Use of low-dose aspirin prior to a newer type of fecal occult blood test is associated with a higher sensitivity for detecting advanced colorectal tumors, compared to no aspirin use, according to a study in the December 8 issue of JAMA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yian Jin Jones, MD 4405 Hamilton Blvd, Sioux City, IA 51104-1140 Ph: (712) 239-3937 | Dr Yian Jin Jones, MD 4405 Hamilton Blvd, Sioux City, IA 51104-1140 Ph: (712) 239-3937 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).
The Nordic Public Health Prize 2011 will be awarded to Professor of Psychiatry Jouko Lönnqvist for his internationally acclaimed research on the causes, spread and prevention of mental illness at population- and individual level.
The U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
Use of low-dose aspirin prior to a newer type of fecal occult blood test is associated with a higher sensitivity for detecting advanced colorectal tumors, compared to no aspirin use, according to a study in the December 8 issue of JAMA.
› Verified 4 days ago
Dr. Charles Earl Jones, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4405 Hamilton Blvd, Sioux City, IA 51104 Phone: 712-239-3937 Fax: 712-239-4946 | |
Dr. Jason Jonathan Jones, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4405 Hamilton Blvd, Sioux City, IA 51104 Phone: 712-239-3937 Fax: 712-239-4946 | |
Dr. Michael G Wadzinski, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5855 Sunnybrook Dr., Sioux City, IA 51106 Phone: 712-226-3937 Fax: 712-224-3973 |